KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Equity Average (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 15 years of Equity Average data on record, last reported at $3.8 billion in Q3 2025.

  • For Q3 2025, Equity Average fell 3.38% year-over-year to $3.8 billion; the TTM value through Sep 2025 reached $3.8 billion, down 3.38%, while the annual FY2024 figure was $3.9 billion, 14.77% up from the prior year.
  • Equity Average reached $3.8 billion in Q3 2025 per JAZZ's latest filing, down from $3.9 billion in the prior quarter.
  • Across five years, Equity Average topped out at $4.1 billion in Q1 2025 and bottomed at $2.9 billion in Q4 2022.
  • Average Equity Average over 5 years is $3.7 billion, with a median of $3.7 billion recorded in 2024.
  • Peak YoY movement for Equity Average: skyrocketed 33.26% in 2021, then dropped 26.32% in 2022.
  • A 5-year view of Equity Average shows it stood at $4.0 billion in 2021, then fell by 26.23% to $2.9 billion in 2022, then increased by 23.93% to $3.6 billion in 2023, then rose by 14.37% to $4.1 billion in 2024, then fell by 7.25% to $3.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $3.8 billion in Q3 2025, $3.9 billion in Q2 2025, and $4.1 billion in Q1 2025.